Antagonists in the Medical Management of Opioid Use Disorders: Historical and Existing Treatment Strategies

Adam Bisaga, MD, Paolo Mannelli, MD, Maria A. Sullivan, MD, PhD, Suzanne K. Vosburg, PhD, Peggy Compton, PhD, RN, George E. Woody, MD, Thomas R. Kosten, MD

1Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York
2Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina
3Alkermes Inc., Waltham, Massachusetts
4Scientific Consultant, Edgewater, New Jersey
5Department of Family and Community Health, School of Nursing, University of Pennsylvania, Philadelphia, Pennsylvania
6Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
7Baylor College of Medicine, Houston, Texas

Background and Objectives: Opioid use disorder (OUD) is a chronic condition with potentially severe health and social consequences. Many who develop moderate to severe OUD will repeatedly seek treatment or interact with medical care via emergency department visits or hospitalizations. Thus, there is an urgent need to develop feasible and effective approaches to help persons with OUD achieve and maintain abstinence from opioids. Treatment that includes one of the three FDA-approved medications is an evidence-based strategy to manage OUD. The purpose of this review is to address practices for managing persons with moderate to severe OUD with a focus on opioid withdrawal and naltrexone-based relapse-prevention treatment.

Methods: Literature available on PubMed was used to review the evolution of treatment strategies from the 1960s onward to manage opioid withdrawal and initiate treatment with naltrexone.

Results: Emerging practices for extended-release naltrexone induction include the use of agonist tapers and adjuvant medications. Clinical challenges frequently encountered when initiating this therapy include managing withdrawal and ongoing opioid use during treatment. Clinical factors may inform decisions regarding patient selection and length of naltrexone treatment, such as recent opioid use and patient preferences.

Conclusions and Scientific Significance: Treatment strategies to manage opioid withdrawal have evolved, but many patients with OUD do not receive medication for the prevention of relapse. Clinical strategies for induction onto extended-release naltrexone are now available and can be safely and effectively implemented in specialty and select primary care settings. (© 2018 The Authors. The American Journal on Addictions – 27:177–187)

INTRODUCTION

A drug overdose crisis exists in the United States, with the majority (>60%) of deaths involving an opioid such as heroin, fentanyl, and carfentanil.1 The 2016 National Survey on Drug Use and Health survey indicated that, within the past year, approximately 2 million Americans aged 18 or older had an opioid use disorder (OUD) involving prescription pain relievers or heroin.2 OUD is a chronic and relapsing condition with severe health, social, and societal consequences; many who develop it repeatedly seek treatment or interact with medical care via emergency department visits or hospitalizations for infections, overdoses, or other substance-related complications. Moderate to severe OUD as defined by the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) (DSM-5)3 roughly corresponds to opioid dependence as defined by the DSM-IV4 and will be addressed in this review.

Extensive evidence reveals that pharmacotherapy with an opioid receptor agonist (methadone), partial agonist (buprenorphine), or long-acting injection formulation of the opioid antagonist naltrexone (XR-NTX) improves outcomes in patients treated for OUD. The most common treatment approach to OUD involves opioid cessation and management of opioid withdrawal, typically a week-long process also known as “detoxification,” followed by relapse-prevention psychosocial therapy in residential or outpatient settings, with encouragement to participate in self-help groups. Psychosocial therapy helps patients adopt healthier nondrug-using lifestyles, with medications providing further symptomatic support during this lengthy transition.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Received September 8, 2017; revised March 2, 2018; accepted March 3, 2018.

Address correspondence to Dr. Bisaga, Department of Psychiatry, New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, 1051 Riverside Dr., Unit #120, New York, NY 10032.
E-mail: adam.bisaga@nyspi.columbia.edu
Although an approach that does not include medications to prevent relapse works for some patients (e.g., those treated in long-term residential programs), evidence has repeatedly associated this approach with high rates of relapse and complications, including fatal overdose. Thus, clinical experts favor OUD treatments that include maintenance medications because they are consistent with evidence and constitute adequate care.

Pharmacological management usually involves maintenance treatment with an opioid receptor agonist or a partial agonist, and this approach has the most extensive evidence supporting its long-term effectiveness. An advantage of agonist treatment is that it can be started in outpatients while minimizing the severity and duration of opioid withdrawal. Both methadone and buprenorphine are listed by the World Health Organization (WHO) as essential medications to treat OUD; in the United States, both are approved by the US Food and Drug Administration (FDA) for the treatment of opioid dependence/addiction. Methadone and buprenorphine have been shown to increase adherence to antiretroviral therapy in HIV-infected drug users and to increase treatment retention of opioid-dependent pregnant women. Recently, longer-acting formulations of buprenorphine have been developed, including a monthly injection. Additional research is ongoing to evaluate an extended-release buprenorphine implant in Phase 3 randomized clinical trials.

An alternative strategy involves treatment with an opioid receptor antagonist such as naltrexone. Naltrexone administration requires prior completion of opioid withdrawal, typically with 7–10 days having passed since the last opioid dose; otherwise, it may precipitate significant opioid withdrawal. Oral naltrexone, a formulation that requires daily administration, has been available for clinical use in the United States since the 1970s. It is recognized in WHO treatment guidelines for preventing relapse in patients who have withdrawn from opioids and is FDA-approved for the blockade of the effects of exogenously administered opioids. However, problems with adherence to a daily medication regimen followed by treatment dropout have limited the effectiveness of oral naltrexone in clinical practice. In 2010, an extended-release injectable naltrexone (XR-NTX) formulation that provides an opioid blockade for approximately 1 month after a single dose was FDA-approved for the prevention of relapse to opioid dependence following opioid detoxification as part of an individualized comprehensive management program that includes psychosocial support.

This long-acting formulation can be given in a wide range of clinical settings, including primary care and criminal justice systems. However, there is limited experience with this drug medication outside specialized treatment settings. XR-NTX has frequently been offered to patients who have completed extended residential treatment and to patients for whom initiation of relapse-prevention treatment with XR-NTX was relatively uncomplicated because of current abstinence. Most patients in need of treatment, however, are actively using opioids at the time of initial evaluation and require completion of opioid withdrawal before XR-NTX initiation. Although medically supervised management of withdrawal in the inpatient setting is optimal, the availability of inpatient treatment in the United States is limited and where it exists is often restricted to a few days. Therefore, feasible and effective outpatient approaches to manage opioid withdrawal for patients seeking treatment with XR-NTX are needed.

This review describes the evolution of treatment strategies to manage opioid withdrawal and initiate treatment with XR-NTX, with a focus on the outpatient setting, and discusses emerging XR-NTX induction practices, challenges frequently encountered when initiating XR-NTX, and clinical factors helpful in identifying patients suitable for opioid antagonist treatment. Literature available on PubMed was used to review the evolution of treatment strategies from the 1960s onward to manage opioid withdrawal and initiate treatment with naltrexone.

**HISTORICAL PERSPECTIVE ON CLINICAL MANAGEMENT OF OPIOID WITHDRAWAL AND INITIATING TREATMENT WITH NALTREXONE**

Medical management of OUD has continued to evolve since the first widespread treatments were introduced in the 1960s (Fig. 1). For many years, medical management of OUD...
has focused on alleviating withdrawal\textsuperscript{17}; however, this approach has been repeatedly shown to be insufficient for ensuring long-term abstinence. OUD is now recognized as a chronic disorder that persists beyond the acute withdrawal period and, therefore, is insufficiently managed with short-term interventions. Observable neuroadaptive changes in the brain may explain the high levels of relapse that characterize substance use disorders.\textsuperscript{18} Medications have been developed to address these changes and treat OUD. In addition, patient education and counseling to reduce the ongoing impact of OUD are important for increased adherence and improved treatment outcomes.

However, medication-based approaches for the long-term management of OUD are underutilized because, despite clear evidence that short-term medication treatments are insufficient, practitioners and treatment programs often focus on alleviating acute withdrawal and discontinuing medication support once acute opioid withdrawal has resolved. Accordingly, rates of opioid use resumption and overdose among patients treated for OUD remain high.\textsuperscript{19}

**Gradual Methadone Taper: 1960s and 1970s**

A major advance in OUD treatment was the introduction of methadone maintenance in the early 1960s as a strategy to reduce drug use, mortality, morbidity, and other adverse consequences of heroin addiction. Methadone was initially proposed as a time-limited approach; when patients achieved treatment goals and wanted to discontinue medication support, standard practice involved a slow dose taper over 14–180 days.\textsuperscript{20–22} Using this approach, anywhere from 8% to 79% of patients achieved an opioid free state, with the proportion of patients remaining opioid free generally decreasing with longer periods of observation.\textsuperscript{23} Further research indicated that a longer tapering period increased treatment retention, but even with longer tapers, intolerable withdrawal and craving were not eliminated and led some patients to discontinue treatment, resume illicit opioid use, or ask that the dose tapering be stopped or reversed.\textsuperscript{22,24} In summary, time-limited use of methadone puts patients at risk and should generally be avoided, regardless of the schedule of methadone discontinuation.

**Clonidine: Late 1970s to Early 1980s**

Low rates of methadone discontinuation and persisting discomfort despite very slow tapers led to the use of adjunctive “non-opioid” medications that targeted residual signs and symptoms of opioid withdrawal. Beginning in the 1970s, these efforts aimed to reduce hyper-arousal and anxiety, both dominant features of opioid withdrawal, by decreasing adrenergic transmission. Clonidine, an \( \alpha \)-2 adrenergic agonist, was found to achieve these results via inhibiting noradrenergic activity in the locus coeruleus, and enabled some patients to discontinue chronic methadone treatment during a 14-day inpatient treatment episode.\textsuperscript{25} However, concerns arose that higher doses of clonidine were often needed to suppress withdrawal, producing significant hypotension while offering only partial relief of the discomfort, craving, and other symptoms of withdrawal, resulting in treatment dropout and relapse.\textsuperscript{26} However, clonidine continues to be used as an adjunct during opioid withdrawal to provide limited symptomatic relief.

**Naltrexone: 1970s**

As clinical observations and studies repeatedly found that completing opioid withdrawal was insufficient to assure continuing abstinence, in the 1970s a new approach was proposed that involved naltrexone, an opioid receptor “blocker,” to prevent relapse after detoxification.\textsuperscript{27} Clinical trials evaluated oral naltrexone as a relapse-prevention strategy.\textsuperscript{28} Initiation of naltrexone treatment, defined as tolerating 50 mg, was identified as a useful “endpoint” for opioid-withdrawal treatment.\textsuperscript{29} The main challenge was that introducing naltrexone too early following opioid discontinuation precipitated withdrawal. An additional challenge was poor adherence to daily dosing and resultant treatment dropout during the first weeks of treatment, as patients continued to experience cravings and symptoms of protracted withdrawal, which they often attributed to naltrexone.\textsuperscript{30}

**Clonidine + Naltrexone: 1980s**

Clonidine and other adjunctive medications rendered the patient experiencing withdrawal more comfortable, but did not shorten its duration.\textsuperscript{26} Although administering a low dose of an opioid receptor antagonist (naloxone or naltrexone) shortened withdrawal by 2–4 days, withdrawal symptom severity was exacerbated. Thus began the process of introducing rapid (accelerated) withdrawal by administering naltrexone 1–2 days after the last opioid dose,\textsuperscript{31} in combination with adjunctive medications such as clonidine and benzodiazepines, to ameliorate the symptoms of withdrawal.\textsuperscript{29,32}

The naltrexone plus clonidine regimen was refined throughout the 1980s and first used in an inpatient setting with methadone-maintained patients. As the usual daily dose of naltrexone (50 mg/day) was too high for use within 1 or 2 days of opioid cessation, in these early studies, clonidine was administered from the first day of treatment, and naltrexone (at starting doses of 1–12.5 mg/day) was introduced on the second day and rapidly up-titrated to 50 mg by Day 5.\textsuperscript{29,33–35} Doses of adjunctive clonidine and benzodiazepines continued to be administered, as needed, for anxiety, or insomnia at decreasing doses.\textsuperscript{29} This protocol was later amended to include standing doses of benzodiazepines and other medications to decrease muscle pain and gastrointestinal hypermotility.\textsuperscript{36} Subsequent studies further supported the use of non-opioid medications in managing withdrawal from methadone and heroin, in both inpatient and outpatient settings.\textsuperscript{34,37}

**Clonidine + Naltrexone + Buprenorphine: Late 1980s–1990s**

Buprenorphine, a partial opioid receptor agonist with a long half-life, was first proposed as an OUD treatment in the late
Although several studies showed that gradual outpatient buprenorphine tapers result in low rates of opioid abstinence (7–22% at 1 month), \textsuperscript{39–41} buprenorphine as maintenance therapy or for use in transition to other medications resulted in greater success. Patients treated with buprenorphine for the discontinuation of methadone or heroin exhibited milder withdrawal symptoms; therefore, buprenorphine gained acceptance as a medication that enabled easier transition onto naltrexone. \textsuperscript{23,42–45}

Combining Opioid Agonists With Very-Low-Dose Naltrexone: 1990s–2000s

The use of very-low-dose (<1 mg) naltrexone to assist with opioid withdrawal evolved from the observation of a methadone-maintained patient who accidentally ingested 50 mg of naltrexone and after an initial period of withdrawal remained symptom-free, even with significant blood levels of both drugs. \textsuperscript{46} The observation spurred the development of a very-low-dose naltrexone paradigm wherein patients received increasing doses of naltrexone, starting at .125 mg and reaching a full therapeutic dose of 50 mg, while concurrent methadone was rapidly tapered. Adjuvant medications were also used and the procedure was accomplished within 6 days. \textsuperscript{46–48} However, while very-low-dose naltrexone reduced withdrawal and craving, treatment retention or success was not improved. \textsuperscript{49,50}

Naltrexone + Buprenorphine as Precursors to Extended-Release Naltrexone: Early 2000s

The early and mid-2000s saw a revival of naltrexone induction studies, primarily due to potentially improved treatment adherence with extended-release formulations of naltrexone. Newer protocols focused on identifying optimal doses and treatment durations of buprenorphine, naltrexone, and clonidine to shorten induction periods, while minimizing the severity of withdrawal. Major changes to earlier protocols involved reducing buprenorphine treatment to 1–2 days, shortening to 1 day the “washout” period before starting naltrexone, and decreasing the first dose of naltrexone from 12.5 to 3 mg, with supportive medications, usually standing doses of clonidine and clonazepam administered at frequent dosing intervals. \textsuperscript{51–57} A 2017 study comparing outpatient detoxification regimens showed that an oral naltrexone-assisted detoxification regimen, compared with a descending buprenorphine taper followed by a 7-day washout period, was more likely to lead to successful XR-NTX induction (56% vs. 33%) and a second XR-NTX dose (50% vs. 27%). \textsuperscript{58}

Extended-Release Naltrexone: 2010s

Many patients starting treatment with oral naltrexone have difficulty adhering to a daily regimen, \textsuperscript{59,60} a pattern often correlated with poor treatment retention and relapse. \textsuperscript{61,62} Poor adherence to daily oral medication spurred the development of extended-release injectable and implantable formulations that would eliminate the need for daily decisions to take a medication. \textsuperscript{53,63–67}

XR-NTX is a 380-mg dose of naltrexone-containing biodegradable microspheres administered as suspension by monthly intramuscular injections approved by the FDA in 2010 as Vivitrol for prevention of relapse to opioid dependence. Naltrexone implants have been developed and used in Australia, \textsuperscript{68} and one \textsuperscript{49} is approved and used in Russia. In the United States, compounding pharmacies have manufactured implants, but none has received FDA approval.

Patients treated with XR-NTX (implants or injectable) have less treatment dropout, lower rates of opioid use, and reduced craving, as compared with patients treated with placebo. \textsuperscript{53,64,70} Persons on probation or parole who were randomly assigned to an open-label treatment with XR-NTX compared with treatment as usual had significantly lower rates of relapse, longer relapse-free survival, lower rates of heroin use, and fewer overdoses over a 24-week treatment period, with a loss of effect seen at 28 and 54 weeks after the end of treatment. \textsuperscript{71} A study using historical controls found that patients treated with XR-NTX had higher retention rates and less relapse than patients treated with oral naltrexone. \textsuperscript{72} Recent studies directly comparing the efficacy of XR-NTX and buprenorphine/naloxone show that among patients who successfully initiated treatment with medications, treatment outcomes were comparable. \textsuperscript{73,74}

CURRENT APPROACH TO TREATMENT OF OPIOID USE DISORDER: CHOOSING THE PHARMACOLOGICAL APPROACH

Although long-term follow-up data may be available for individual medications, \textsuperscript{75,76} limited data are available from controlled studies or long-term observational cohort follow-up studies providing head-to-head comparisons of medications for managing OUD. Treatment availability, health coverage limitations, or a patient’s preferences often determine the treatment used. Nevertheless, it is important that the provider engage the patient in a process of shared decision-making to arrive at the most appropriate treatment plan, involving a discussion of all available treatments including residential, office-based pharmacotherapy, and addiction treatment programs that offer FDA-approved medications. Important discussion topics include the differences among methadone, buprenorphine, and naltrexone; requirements for treatment initiation; risks; benefits; side effects; possible interactions with other medications; the chronic nature of treatment; treatment dropout or termination issues; and the logistics associated with various treatment options (e.g., daily visits for methadone; less often for buprenorphine; monthly visits for XR-NTX). When possible, the final discussion should involve a family member or significant other to facilitate adherence. The provider may assess the patient’s motivation for treatment and medication preferences before offering a final recommendation for a specific medication, along with alternatives if there are problems with the first choice. \textsuperscript{7} In cases where a provider
lacks expertise or certification, patients can be referred to
another provider.

Methadone maintenance is the most studied approach and
should be offered to all patients seeking treatment for OUD.
Patients who have previously found methadone effective
should be encouraged to continue using methadone mainte-
nance. Many patients will opt for agonist approach, but some
do not want it, and will only seek treatment in
settings where it is available, agree only to short-term
agonist treatment, or will want to try something else. For
these patients, evidence largely suggests that a slow agonist
taper provides superior outcomes to a rapid taper, although
conflicting results have been reported. Some patients,
however, despite having been successfully treated with
agonists long-term, may be unable to complete the taper
and may have to resume agonist maintenance. Others will only
agree to short-term agonist treatment to alleviate withdrawal,
despite having experienced its high failure rate. For these
patients, XR-NTX may represent a viable treatment.

Initiating Antagonist Treatment With Extended-
Release Naltrexone (Induction)

Despite its demonstrated efficacy, tolerability, and monthly
dosing, XR-NTX remains underutilized in community-based
treatment programs. Reasons include the novelty of this
approach, a small number of published effectiveness trials,
high dropout rates from oral naltrexone in earlier studies, low
penetration into formularies, and concerns about treatment
cost. Other reasons include lack of knowledge and experience
of providers, particularly regarding strategies to initiate
treatment safely, alleviate distress associated with early
abstinence, and provide concurrent psychosocial treatment
to address lifestyle changes and use of alcohol and non-opioid
drugs. Strategies to increase the success of transition of active
opioid users onto XR-NTX treatment remain key to the
success of long-term relapse-prevention treatment.

Initiating XR-NTX treatment is relatively straightforward
in patients who are not physiologically dependent on opioids,
such as persons leaving a controlled setting (e.g., residential
treatment program or correctional facility). The first dose of
XR-NTX can be administered once the patient is confirmed to
be abstinent from opioids by urine toxicology, and the
clinician may give an optional naloxone challenge to confirm
the resolution of physiological dependence. Because of
buprenorphine’s tighter binding to opioid receptors, naloxone
may not precipitate withdrawal in patients using buprenor-
phine, highlighting the need to ensure that urine drug testing
includes testing for buprenorphine. In our experience, a trial
period of treatment with oral naltrexone is not recommended
prior to the first XR-NTX injection because patients are less
likely to adhere to it and experience relapse. Some
practitioners, however, may choose to administer a single
dose of 25–50 mg oral naltrexone after establishing the
absence of physiological opioid dependence, to confirm
tolerability, and then provide the first XR-NTX injection
1–2 hours later. It should be noted that a recent study
demonstrated that, when used for 1–7 days as a detoxification
agent, buprenorphine may not require a subsequent 7-day
washout period.

However, most patients presenting for treatment are
actively using opioids at the time of evaluation. In such
patients, initiating XR-NTX treatment requires that the patient
first complete opioid withdrawal. To minimize the risk of
precipitated withdrawal, it is recommended that patients have
at least 7–10 days of washout after their last use of opioids. The
patient then receives an injection of 380 mg XR-NTX
provided the absence of physiological dependence is
confirmed by urine testing and naloxone challenge. A common
procedure involves a short-term (e.g., 7- to 14-day) buprenor-
phine taper followed by 7–10 days of washout prior to the first
XR-NTX dose (Table 1). To reduce the risk of premature
treatment dropout and relapse, a shorter induction is preferable
if the risk of precipitated withdrawal can be avoided or
minimized.

Two procedures may shorten the induction period follow-
ing abrupt opioid agonist discontinuation. First, buprenor-
phine can be given for 1 day, as it replaces the full agonist at
the receptor, while providing partial agonist activity to prevent
significant withdrawal. Buprenorphine is then followed by 1–2
days of washout and a gradual ascending titration of oral
naltrexone over the subsequent 3–5 days, beginning with a low
dose of 1–3 mg. Throughout this procedure, patients receive
standing doses of adjunctive medications, usually clonidine
and clonazepam (Table 1). The second procedure employs
buprenorphine taper in combination with very low doses of
oral naltrexone (≤1 mg/day) over the first 2–3 days, followed
by a gradual up-titration of naltrexone to full blocking doses
(≥25 mg/day), usually accomplished within 7 days (Table 2).
These procedures have allowed 50–70% of outpatients to
successfully initiate treatment with XR-NTX with favorable
tolerability and no serious adverse events due to
precipitated withdrawal.

Stabilizing Patients on Extended-Release
Naltrexone

XR-NTX should be part of an individualized comprehensive
management program that includes psychosocial sup-
port. Initiation of treatment with XR-NTX shortly after
completion of opioid withdrawal, or lack of confirmation of
the absence of current opioid dependence or recent bupre-
orphine use, may result in protracted withdrawal-like
symptoms for several weeks. Symptoms can include sleep
disturbances, low energy, anxiety, irritability, and diarrhea
that slowly resolve over days to weeks. To alleviate
protracted withdrawal, several medication strategies have
been proposed, including methylphenidate and quetiapine,
and cannabis may also have a therapeutic benefit.

Managing Ongoing Opioid Use in Patients Being
Treated With Extended-Release Naltrexone

Up to one third of patients who receive XR-NTX use illicit
opioids at some point during treatment, commonly as single
A recent study of patients using opioids during XR-NTX blockade found that most did not feel euphoria and used lower doses than before receiving XR-NTX. Most patients reported testing the blockade during the first weeks after the injection (median, 2.4 weeks). Some patients continue using opioids for several weeks after XR-NTX induction, but this practice usually has not been associated with worse long-term outcomes and rarely continues if the patient receives XR-NTX as scheduled. Based on our clinical experiences, continuous blockade prevents patients from becoming physiologically re-dependent, and many patients prefer to remain on XR-NTX despite occasional brief episodes of use. Very few patients appear to intentionally override the blockade. However, an attempt to override the blockade may lead to opioid intoxication or fatal opioid overdose, a fact that should be communicated to patients. Last, patients with OUD treated with XR-NTX or naltrexone implant report reduced craving, an effect possibly related to blocking beta-endorphin release in response to triggers or cues.

### Safety of Long-Term Treatment With Extended-Release Naltrexone

XR-NTX is generally well tolerated in patients with OUD. Adverse events may include injection site pain, nausea, headaches, nasopharyngitis, insomnia, and toothache. A recently completed 2-year open-label study of healthcare professionals with opioid dependence showed XR-NTX to have levels of safety similar to those seen in shorter-term studies. Vulnerability to an overdose is an important consideration in patients with OUD who drop out of antagonist or agonist treatment. In the case of naltrexone, after opioid detoxification or if a scheduled dose is missed, patients have reduced tolerance to opioids and are vulnerable to overdose. Although opioid antagonists up-regulated μ-receptors and induced supersensitivity to morphine in a mouse model, healthy humans show no evidence of μ-receptor up-regulation in the respiratory control system, the most likely site of opioid overdose lethality. Overall, the risk of overdose is significantly lower in patients who are actively involved in medication-assisted treatment whether it is with methadone, buprenorphine, or naltrexone.

Attempts to override the antagonist blockade, however, can result in fatal overdose, which should be discussed with patients at each treatment visit.

In a recent 6-month randomized study with a 78-week follow-up period, no overdoses were reported in the 153 enrolled patients treated with XR-NTX, compared with seven overdoses in the treatment-as-usual group (brief counseling and referrals for community treatment programs). Patients treated with oral naltrexone had a higher risk of overdose than those treated with methadone or naltrexone implants; the risk was comparable in patients maintained on methadone or naltrexone implants. In two recent large comparative effectiveness trials of XR-NTX versus buprenorphine-naloxone, risk of overdose was similar.

### TABLE 1. Initiating treatment with extended-release naltrexone (inpatient and outpatient)

| Day | Standard induction procedure | Inpatient procedure with 1 day of BUP | Outpatient procedure with 1 day of BUP |
|-----|-----------------------------|-------------------------------------|--------------------------------------|
| 1   | Patients instructed to remain abstinent for 7–10 days from all opioids except those prescribed as part of the induction protocol | Patient comes to clinic in mild–moderate withdrawal. Give buprenorphine starting at 2 mg, titrate up to 8 mg as tolerated | Patient comes to clinic in mild–moderate withdrawal. Give buprenorphine starting at 2 mg, titrate up to 8 mg as tolerated |
| 2   | Washout days | Washout day | Washout day |
| 3   | Induct and administer buprenorphine 8 mg | Initiate titration of oral naltrexone (total daily doses): 1, 3, 12, and 25 mg | Initiate titration of oral naltrexone (total daily doses): 1, 3, 12, and 25 mg |
| 4   | Increase daily doses of oral naltrexone: 3, 12.5, 25, and 50 mg | Give buprenorphine starting at 2 mg, titrate up to 8 mg as tolerated | Give buprenorphine starting at 2 mg, titrate up to 8 mg as tolerated |
| 5   | Administer XR-NTX 380 mg injection | Administer XR-NTX 380 mg injection | Administer XR-NTX 380 mg injection |
| 6   | Day 8–11: Administer naloxone challenge followed by XR-NTX 380 mg injection | Day 8–11: Administer naloxone challenge followed by XR-NTX 380 mg injection | Day 8–11: Administer naloxone challenge followed by XR-NTX 380 mg injection |
| 7   | Adjuvant medications: clonidine, diazepam, prochlorperazine, trazodone, zolpidem | Adjuvant medications: clonidine, diazepam, prochlorperazine, trazodone, zolpidem | Adjuvant medications: clonidine, diazepam, prochlorperazine, trazodone, zolpidem |

BUP, buprenorphine; XR-NTX, extended-release naltrexone.

*Doses of naltrexone less than 50 mg are not commercially available and require a compounding pharmacy for dispensing.*

**Note:** Episodes to “test” the blocking effect of the medication. Episodes to “test” the blocking effect of the medication.
in the XR-NTX (n = 2/283 and n = 0/71, respectively) and buprenorphine (n = 3/287 and n = 1/72, respectively) groups. Notably, patients dropping out of treatment with methadone or buprenorphine were also at elevated risk of overdose. 97,98

Clinicians are advised to monitor patients on XR-NTX for the emergence of depressive symptoms. In a 24-week trial of XR-NTX for alcohol dependence (N = 624), depressive symptoms were reported by 10% of patients treated with XR-NTX, compared with 5% of patients treated with placebo. 99 However, depressed mood or suicidal thinking was not reported by patients treated with either XR-NTX or placebo in the pivotal XR-NTX trial (N = 250). 64 and psychiatric adverse effects occurred at comparable rates in recent reports of patients treated with buprenorphine and XR-NTX. 73,74 Studies have demonstrated that depressive symptoms, often present at treatment entry, improve with opioid abstinence whether in the setting of receipt of oral naltrexone, XR-NTX, or placebo. 70,100,101 Adherence to oral naltrexone has been associated with fewer depressive symptoms than non-adherence 102 and depressive symptoms improved significantly during the first month of treatment with XR-NTX. 103

### Selection of Patients Suitable for Extended-Release Naltrexone

Patients who have been successfully treated with opioid agonists but would like to taper off them may be suitable candidates for XR-NTX because discontinuation of opioid agonist treatment frequently leads to relapse. 77,104 According to a recent survey of patients undergoing opioid withdrawal, patients preferred XR-NTX (32%) over buprenorphine (28%) or methadone (18%), 77 underscoring the importance of presenting patients seeking treatment for OUD with the full range of agonist and antagonist choices.

A secondary analysis of the pivotal study that led to FDA approval of XR-NTX for opioid dependence 85 did not reveal any baseline patient characteristics associated with treatment outcome. 105 although particularly severe, unstable psychosocial conditions may interfere with retention. 108 Because most trials have been conducted in adults, limited information is available on adolescents and young adults. 107,108

### SUMMARY AND FUTURE DIRECTIONS

1. This review aimed to describe the evolution of treatment strategies to manage opioid withdrawal and to place the use of XR-NTX as a relapse-prevention strategy in OUD into the historical context of several decades of clinical research.
2. Standard practice for managing OUD remains maintenance treatment with methadone or buprenorphine.
3. Many patients are treated with medications to alleviate opioid withdrawal but are not offered medication support afterward, a strategy with a high failure rate and a significant risk of overdose.
4. Clinical strategies for XR-NTX initiation have evolved considerably. Common treatment protocols that address the recommendation for a 7- to 10-day opioid-free duration prior to transitioning to XR-NTX are now available and can be safely and effectively implemented in specialty and select primary care settings.

### TABLE 2. Using very low doses of naltrexone to initiate treatment

| Day | Outpatient procedure 83 |
|-----|-------------------------|
| 1–3 | Patients instructed to remain abstinent for 24 hours from all opioids except those prescribed as part of the induction protocol |
| 4–7 | Increase daily dose of oral naltrexone (.25–1 mg)* as tolerated, decrease daily dose of buprenorphine (4–2 mg) |
| 8   | Discontinue buprenorphine and increase daily dose of naltrexone to 30–50 mg by Day 7 |
| As necessary | Adjunct medications: trazodone, cyclobenzapine, lorazepam, hydroxyzine |

XR-NTX, extended-release naltrexone.

* Doses of naltrexone less than 50 mg are not commercially available and require a compounding pharmacy for dispensing.

Chronic pain 109 poses an additional challenge in using antagonists. More research is needed to understand the risks associated with naltrexone during pregnancy 110 although recent data suggest comparable obstetric outcomes. 111 XR-NTX may be used in patients with mild renal or mild/moderate hepatic impairment with no dose adjustments. 12

Oral naltrexone and XR-NTX have been shown to benefit patients who are motivated for abstinence due to employment-based negative contingencies, such as healthcare professionals or business executives. 90,112,113 Combining XR-NTX with employment-based reinforcement has also been shown to be effective in unemployed adults. 114 Others who may benefit include incarcerated persons and those without access to opioid agonist treatment. 90,71,115 Criminal justice offenders treated with XR-NTX had double the median length of opioid-free time compared with those who received brief counseling and a referral to community treatment. 71 Positive outcomes extended to offenders with multiple diagnoses, including HIV 116 and drug court-involved persons. 117
(5) XR-NTX is generally well tolerated in patients with OUD. Vulnerability to an overdose is an important consideration in patients who drop out of antagonist or agonist treatment or who are detoxified or released from correctional facilities without follow-up medication-assisted treatment.

(6) Suitable candidates for XR-NTX treatment may include patients with OUD who do not want to initiate or continue treatment with an opioid agonist and patients who live where agonists are not easily accessible.

Suzanne K. Vosburg is an independent scientific consultant who provided literature review and medical writing for the manuscript, which was funded by Alkermes, Inc. Editorial support for the manuscript was provided by ApotheCom and funded by Alkermes, Inc. Authors also acknowledge the organizational support of Hajira Koeller, PhD, and Alexandra Silveira, PhD, employees of Alkermes, Inc.

Declaration of Interest

Adam Bisaga, MD, has received honoraria, consultation fees, travel reimbursement for training, medical editing, market research from UN Office on Drugs, Crime, Motive Medical Intelligence, Healthcare Research Consulting Group, GLG Research Group, Guidepoint Global. Dr. Bisaga received compensation from Indivior for an unbranded educational activity. He received pharmaceutical products extended-release naltrexone from Alkermes for NIH-funded research studies, was an investigator for a multisite clinical trial funded by Alkermes, he served as an unpaid consultant to Alkermes. Paolo Mannelli, MD, received consultation fees from Guidepoint Global and Alkermes, Inc., research funding from Alkermes, and is an investigator for a multisite clinical trial funded by Alkermes. Maria A. Sullivan, MD, PhD, is an employee of Alkermes, Inc. and had received pharmaceutical products (extended-release naltrexone) from Alkermes for NIH-funded research studies. Suzanne K. Vosburg, PhD, is a research consultant and writer who contracts with multiple companies requiring independence of perspective. She contracted with Alkermes, Inc. for preparation of this paper. Peggy Compton PhD, RN, does not have any conflicts of interest. George Woody, MD, has received from Alkermes extended-release injectable naltrexone (VIVITROL) or corresponding placebo control for clinical studies in the United States, Iceland, and Russia, and received honoraria from Alkermes, Inc., and Fidelity Capital has provided implant naltrexone at reduced cost for studies in Russia. Thomas Kosten, MD, has received honoraria from Alkermes, Inc. and is an investigator for a multisite clinical trial funded by Alkermes, Inc.

REFERENCES

1. Rudd R, Seth P, David F, et al. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65:1445–1452.

2. Substance Abuse and Mental Health Services Administration Key Substance Use and Mental Health Indicators in the United States: Results From the 2016 National Survey on Drug Use and Health. Rockville, MD: HHS Publication No. SMA 17–5044, NSDUH Series H-52; 2017.

3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 5th edn. (DSM-5). Arlington, VA: American Psychiatric Association; 2013.

4. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th edn. (Text Revision) (DSM-IV-TR). Arlington, VA: American Psychiatric Association; 1994.

5. Smith LA, Gates S, Foxcroft D. Therapeutic communities for substance-related disorder. Cochrane Database Syst Rev. 2006;Cd000538.

6. Smyth BP, Barry J, Keenan E, et al. Lapse and relapse following inpatient treatment of opiate dependence. Ir Med J. 2010;103:176–179.

7. Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9:358–367.

8. WHO. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. https://www.ncbi.nlm.nih.gov/books/NBK143185/pdf/Bookshelf_NBK143185.pdf. Published 2009. Accessed January 18, 2017.

9. Alice FL, Kamarulzaman A, Soriano VV, et al. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancer. 2010;376:367–387.

10. Jones HE, Martin PR, Heil SH, et al. Treatment of opioid dependent pregnant women: Clinical and research issues. J Subst Abuse Treat. 2008;35:245–259.

11. Izzo M, Guarnieri M. New developments in managing opioid addiction: Impact of a subdermal buprenorphine implant. Drug Des Devel Ther. 2017;11:1429–1437.

12. Vivitrol [package insert]. Waltham, MA: Alkermes; 2015.

13. Cris-t-Christoph P, Lundy C, Stringer M, et al. Extended-release naltrexone for alcohol and opioid problems in Missouri parolees and probationers. J Subst Abuse Treat. 2015;56:54–60.

14. Cousins SJ, Denering L, Creevecoeur-MacPhail D, et al. A demonstration project implementing extended-release naltrexone in Los Angeles County. Subst Abus. 2016;37:54–62.

15. Leslie DL, Milchak W, Gastfriend DR, et al. Effects of injectable extended-release naltrexone (XR-NTX) for opioid dependence on residential rehabilitation outcomes and early follow-up. Am J Addict. 2015;24:265–270.

16. Gordon MS, Kinlock TW, Vocii FJ, et al. A phase 4, pilot, open-label study of VIVITROL® (extended-release naltrexone XR-NTX) for prisoners. J Subst Abuse Treat. 2015;59:52–58.

17. Kleber HD, Ridoran CE. The treatment of narcotic withdrawal: A historical review. J Clin Psychiatry. 1982;43:30–34.

18. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35:217–238.

19. Volkow ND, Frieden TR, Hyde PS, et al. Medication-assisted therapies —Tackling the opioid-overdose epidemic. N Engl J Med. 2014;370:2063–2066.

20. Cusman DH, Dole VP. Detoxification of rehabilitated methadone-maintained patients. JAMA. 1973;226:747–752.

21. Ridoran CE, Mezritz M, Slobetz F, et al. Successful detoxification from methadone maintenance. Follow-up study of 38 patients. JAMA 1976;235:2604–2607.

22. Senay EC, Dorus W, Goldberg F, et al. Withdrawal from methadone maintenance. Rate of withdrawal and expectation. Arch Gen Psychiatry. 1977;34:361–367.

23. Maddux JF, Desmond DP. Methadone maintenance and recovery from opioid dependence. Am J Drug Alcohol Abuse. 1992;18:63–74.

24. Sees KL, DeLucchi KL, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trial. JAMA. 2000;283:1303–1310.
25. Gold MS, Pottash AC, Sweeney DR, et al. Opiate withdrawal using clonidine. A safe, effective, and rapid nonopiate treatment. *JAMA*. 1980;243:343–346.

26. Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. *Drug Alcohol Depend.* 1988;21:253–259.

27. Martin WR, Jasinski DR, Mansky PA. Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. *Arch Gen Psychiatry*. 1973;28:784–791.

28. Julius D, Renault P. Narcotic Antagonists: Naltrexone (Progress Report). NIDA Research Monograph 9. Rockville, MD: US Department of Health, Education, and Welfare; 1976.

29. Charney DS, Riordan CE, Kleber HD, et al. Clonidine and naltrexone. A safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy. *Arch Gen Psychiatry*. 1982;39:1327–1332.

30. Kleber HD, Kosten TR. Naltrexone induction: Psychologic and pharmacologic strategies. *J Clin Psychiatry*. 1984;45:29–38.

31. Riordan CE, Kleber HD. Rapid opiate detoxification with clonidine and naloxone. *Lancet*. 1980;1:1079–1080.

32. Resnick RB, Kestenbaum RS, Washton A, et al. Naloxone-precipitated withdrawal: A method for rapid induction onto naltrexone. *Clin Pharmacol Ther*. 1977;21:409–413.

33. Charney DS, Heninger GR, Kleber HD. The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. *Am J Psychiatry*. 1986;143:831–837.

34. Kleber HD, Riordan CE, Rounsaville B, et al. Clonidine in outpatient detoxification from methadone maintenance. *Arch Gen Psychiatry*. 1985;42:391–394.

35. Vining E, Kosten TR, Kleber HD. Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers. *Br J Addict*. 1988;83:567–575.

36. Brewer C, Rezae H, Bailey C. Opioid withdrawal and naltrexone induction in 48–72 hours with minimal drop-out, using a modification of the naltrexone-clonidine technique. *Br J Psychiatry*. 1988;153:340–343.

37. Kleber HD, Topazian M, Gaspari J, et al. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. *Am J Drug Alcohol Abuse*. 1987;13:1–17.

38. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiction. *Arch Gen Psychiatry*. 1978;35:501–516.

39. Ling W, Hillhouse M, Domier C, et al. Buprenorphine tapering schedule and illicit opioid use. *Addiction*. 2009;104:256–265.

40. Nielsen S, Hillhouse M, Thomas C, et al. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. *J Addict Med*. 2013;7:33–38.

41. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. *Arch Gen Psychiatry*. 2011;68:1238–1246.

42. Kosten TR, Kleber HD. Buprenorphine detoxification from opioid dependence: A pilot study. *Life Sci*. 1988;42:635–641.

43. Kosten TR, Krystal JH, Charney DS, et al. Rapid detoxification from opioid dependence. *Am J Psychiatry*. 1989;146:1349.

44. Stine SM, Kosten TR. Use of drug combinations in treatment of opioid withdrawal. *J Clin Psychopharmacol*. 1992;12:203–209.

45. Umbricht A, Montoya ID, Hoover DR, et al. Naltrexone shortened opioid detoxification with buprenorphine. *Drug Alcohol Depend*. 1999;56:181–190.

46. Mannelli P, De Risio S, Pozzi G, et al. Serendipitous rapid detoxification from opiates: The importance of time-dependent processes. *Addiction*. 1999;94:589–591.

47. Mannelli P, Gotthiel E, Buonanno A, et al. Use of very low-dose naltrexone during opiate detoxification. *J Addict Dis*. 2003;22:63–70.

48. Mannelli P, Patkar AA, Peindl K, et al. Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence. *J Clin Psychopharmacol*. 2007;27:468–474.

49. Mannelli P, Patkar AA, Peindl K, et al. Very low dose naltrexone addition in opioid detoxification: A randomized, controlled trial. *Addict Biol*. 2009;14:204–213.

50. Mannelli P, Patkar AA, Peindl K, et al. Early outcomes following low dose naltrexone enhancement of opioid detoxification. *Am J Addict*. 2009;18:109–116.

51. Rothenberg JL, Sullivan MA, Church SH, et al. Behavioral naltrexone therapy: An integrated treatment for opiate dependence. *J Subst Abuse Treat*. 2002;23:351–360.

52. Sullivan MA, Bisaga A, Glass A, et al. Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone. *Drug Alcohol Depend*. 2015;147:122–129.

53. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for opioid dependence: A randomized, placebo-controlled trial. *Arch Gen Psychiatry*. 2006;63:210–218.

54. Collins ED, Kleber HD, Whittington RA, et al. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: A randomized trial. *JAMA*. 2005;294:903–913.

55. Bisaga A, Sullivan MA, Cheng WY, et al. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. *Drug Alcohol Depend*. 2011;119:e23–e29.

56. Bisaga A, Sullivan MA, Glass A, et al. A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence. *J Subst Abuse Treat*. 2014;46:546–552.

57. Bisaga A, Sullivan MA, Glass A, et al. The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. *Drug Alcohol Depend*. 2015;154:38–45.

58. Sullivan M, Bisaga A, Pavlicova M, et al. Long-acting injectable naltrexone induction: A randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine. *Am J Psychiatry*. 2017;174:459–467.

59. Johansson BA, Berglund M, Lindgren E. Efficacy of maintenance treatment with naltrexone for opioid dependence: A meta-analytical review. *Addiction*. 2006;101:491–503.

60. Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. *Cochrane Database Syst Rev*. 2011;Cd001333.

61. Sullivan MA, Rothenberg JL, Vosburg SK, et al. Predictors of retention in naltrexone maintenance for opioid dependence: Analysis of a stage I trial. *Am J Addict*. 2006;15:150–159.

62. Sullivan MA, Garawi F, Bisaga A, et al. Management of relapse in naltrexone maintenance for heroin dependence. *Drug Alcohol Depend*. 2007;91:289–292.

63. Lobmaier PP, Kunoe N, Gossop M, et al. Naltrexone depot formulations for opioid and alcohol dependence: A systematic review. *CNS Neurosci Ther*. 2011;17:629–636.

64. Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial. *Lancet*. 2011;377:1506–1513.

65. Hulse GK, Norris N, Arnold-Reed D, et al. Improving clinical outcomes in treating heroin dependence: Randomized, controlled trial of oral or implant naltrexone. *Arch Gen Psychiatry*. 2009;66:1108–1115.

66. Krupitsky E, Zvartau E, Blokhina E, et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. *Arch Gen Psychiatry*. 2012;69:973–981.

67. Willette RE. The development of sustained action preparations of narcotic antagonists. *NIDA Res Monogr*. 1976:31–34.

68. Hulse GK, Arnold-Reed DE, O’Neil G, et al. Blood naltrexone and 6-β-naltrexol levels following naltrexone implant: Comparing two naltrexone implants. *Addict Biol*. 2004;9:59–65.

69. Krupitsky E, Zvartau E, Blokhina E, et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. *Arch Gen Psychiatry*. 2012;69:973–981.

70. Krupitsky E, Zvartau E, Blokhina E, et al. Anhedonia, depression, anxiety, and craving in opioid dependent patients stabilized on oral...
71. Lee JD, Friedmann PD, Kinlock TW, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016;374:1232–1242.

72. Brooks AC, Comer SD, Sullivan MA, et al. Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: A quasi-experiment. J Clin Psychiatry. 2010;71:1371–1378.

73. Lee JD, Nunes EV, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): A multicentre, open-label, randomised controlled trial. Lancet. 2018;391:309–318.

74. Tamun L, Solli K, Latif Z, et al. The effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: A randomized clinical noninferiority trial. JAMA Psychiatry. 2017;74:1197–1205.

75. Hser YI, Evans E, Huang D, et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction. 2016;111:695–705.

76. Weiss RD, Potter JS, Griffin ML, et al. Long-term outcomes from the national drug abuse treatment clinical trials network prescription opioid addiction treatment study. Drug Alcohol Depend. 2015;150:112–119.

77. Uelebaker LA, Bailey G, Herman D, et al. Patients’ beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no medication-assisted therapy following inpatient opioid detoxification. J Subst Abuse Treat. 2016;66:48–53.

78. Winstock AR, Lintzeris N, Lea T. “Should I stay or should I go?” Coming off methadone and buprenorphine treatment. Int J Drug Policy. 2011;22:77–81.

79. Dunn KE, Sigmon SC, Strain EC, et al. The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: A review. Drug Alcohol Depend. 2011;119:1–9.

80. Aletraris L, Bond Edmond M, Roman PM. Adoption of injectable naltrexone in U.S. substance use disorder treatment programs. J Stud Alcohol Drugs. 2015;76:143–151.

81. Providers’ Clinical Support System For Medication Assisted Treatment (PCSS-MAT). XR-Naltrexone: A Step-by-Step Guide. http://pcssmat.org/wp-content/uploads/2017/02/Naltrexone_Step-by-Step_Virtual_Brochure-1.pdf. Accessed Apr 4, 2017.

82. Sigmon SC, Bisaga A, Nunes EV, et al. Opioid detoxification and naltrexone induction strategies: Recommendations for clinical practice. Am J Drug Alcohol Abuse. 2012;38:187–199.

83. Mannelli P, Wu LT, Peindi KS, et al. Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: A very low dose naltrexone and buprenorphine open label trial. Drug Alcohol Depend. 2014;138:83–88.

84. Ramsey SE, Rousaville D, Hoskinson R, et al. The need for psychosocial interventions to facilitate the transition to extended-release naltrexone (XR-NTX) treatment for opioid dependence: A concise review of the literature. Subst Abuse. 2016;10:65–68.

85. Ockert DM, Volpicelli JR, Baier AR Jr., et al. Naltrexone for opioid use disorder during chronic opioid withdrawal: A randomized controlled trial. JAMA Psychiatry. 2005;66:1285–1288.

86. Jarvis BP, DeFulio A, Long L, et al. Factors associated with using opiates while under extended-release naltrexone blockade: A descriptive pilot study. J Subst Abuse Treat. 2016;65:56–60.

87. Sullivan MA, Bisaga A, Marianni JJ, et al. Naltrexone treatment for opioid dependence: Does its effectiveness depend on testing the blockade? Drug Alcohol Depend. 2013;133:80–85.

88. Langleben DD, Raparel K, Elman I, et al. Extended-release naltrexone modulates brain response to drug cues in abstinent heroin-dependent patients. Addict Biol. 2014;19:262–271.

89. Early PH, Zammo J, Memisoglu A, et al. Open-label study of injectable extended-release naltrexone (XR-NTX) in healthcare professionals with opioid dependence. J Addict Med. 2017;11:224–230.

90. Sirohi S, Kumar P, Yoburn BC. Mu-opioid receptor up-regulation and functional supersensitivity are independent of antagonist efficacy. J Pharmacol Exp Ther. 2007;323:701–707.

91. Cornish JW, Henson D, Levine S, et al. Naltrexone maintenance. Am J Addict. 1993;2:34–38.

92. Diggust E, Shakeshaft A, Ritter A, et al.Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction. 2004;99:450–460.

93. Gibson AE, Degenhardt LJ. Mortality related to pharmacotherapies for opioid dependence: A comparative analysis of coronial records. Drug Alcohol Rev. 2007;26:405–410.

94. Hulse GK, Tait Rj, Comer SD, et al. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend. 2005;79:351–357.

95. Tait RJ, Ngo HT, Hulse GK. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment. J Subst Abuse Treat. 2008;35:116–124.

96. Cornish R, Macleod J, Strang J, et al. Risk of death during and after opiate substitution treatment in primary care: Prospective observational study in UK General Practice Research Database. BMJ. 2010;341:c5475.

97. Hutchinson SJ, Taylor A, Gruer L, et al. One-year follow-up of opiate injectors treated with oral methadone in a GP-centred programme. Addiction. 2000;95:1055–1068.

98. Garbutt JC, Kranzler HR, O’Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. JAMA. 2005;293:1617–1625.

99. Mozzo K, McCann M, Busch J, et al. Naltrexone and dysphoria: Fact or myth? Am J Addict. 2002;11:151–160.

100. Mysels DJ, Cheng WY, Nunes EV, et al. The association between naltrexone treatment and symptoms of depression in opioid-dependent patients. Am J Drug Alcohol Abuse. 2011;37:22–26.

101. Dean AJ, Saunders JB, Jones RT, et al. Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence. J Psychiatry Neurosci. 2006;31:38–45.

102. Zaatjer ER, van Dijk L, de Bruin K, et al. Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients. Psychopharmacology. 2015;232:2597–2607.

103. Weiss RD, Potter JS, Griffin ML, et al. Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study. Drug Alcohol Depend. 2015;150:112–119.

104. Nunes EV, Krupitsky E, Ling W, et al. Treating opioid dependence with injectable extended-release naltrexone (XR-NTX): Who will respond? J Addict Med. 2015;9:238–243.

105. Cousins SJ, Radfar SR, Crevecoeur-MacPhail D, et al. Predictors of continued use of extended-released naltrexone (XR-NTX) for opioid-dependence: An analysis of heroin and non-heroin opioid users in Los Angeles County. J Subst Abuse Treat. 2016;63:66–71.

106. Fishman MJ, Winstanley EL, Curran E, et al. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: Preliminary case-series and feasibility. Addiction. 2010;105:1669–1676.

107. Woody GE, Poole SA, Subramanium G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial. JAMA. 2008;300:2003–2011.

108. Vowles KE, McIntee ML, Julnes PS, et al. Rates of opioid misuse, abuse, and addiction in chronic pain: A systematic review and data synthesis. Pain. 2015;156:569–576.

109. Jones HE, Chisom LS, Jansson LM, et al. Naltrexone in the treatment of opioid-dependent pregnant women: The case for a considered and measured approach to research. Addiction. 2013;108:233–247.

110. Kelty E, Hulse G. A retrospective cohort study of obstetric outcomes in opioid-dependent women treated with implant naltrexone, oral methadone or sublingual buprenorphine, and non-dependent controls. Drugs. 2017;77:1199–1210.
112. Ling W, Wesson DR. Naltrexone treatment for addicted health-care professionals: A collaborative private practice experience. *J Clin Psychiatry*. 1984;45:46–48.

113. Roth A, Hogan I, Farren C. Naltrexone plus group therapy for the treatment of opiate-abusing health-care professionals. *J Subst Abuse Treat*. 1997;14:19–22.

114. DeFulio A, Everly JJ, Leoutsakos JM, et al. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: A randomized controlled trial. *Drug Alcohol Depend*. 2012;120:48–54.

115. Krupitsky E, Zvartau E, Woody G. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. *Curr Psychiatry Rep*. 2010;12:448–453.

116. Springer SA, Brown SE, Di Paola A, et al. Correlates of retention on extended-release naltrexone among persons living with HIV transitioning to the community from the criminal justice system. *Drug Alcohol Depend*. 2015;157:158–165.

117. Finigan MW, Perkins T, Zold-Kilbourn P, et al. Preliminary evaluation of extended-release naltrexone in Michigan and Missouri drug courts. *J Subst Abuse Treat*. 2011;41:288–293.